Oct 19 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH SUBMITS IND AND ACCOMPANYING FAST TRACK APPLICATION FOR PHASE 2 TRIAL OF AMPLIGEN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LATE-STAGE PANCREATIC CANCER
Source text for Eikon: ID:nGNEMYnyj Further company coverage: AIM.A
((reuters.briefs@thomsonreuters.com;))